OTC • Last print unknown ago
$0.05—Stale · unknown old
PT Kalbe Farma Tbk. is a leading pharmaceutical and healthcare company in Indonesia, specializing in the production of prescription drugs, over-the-counter products, and nutritional supplements. Its competitive position is bolstered by a strong distribution network across Southeast Asia and a diverse product portfolio that addresses various health needs.
Kalbe Farma generates revenue through the sale of a wide range of pharmaceutical products, leveraging its extensive distribution channels and strong brand recognition in Indonesia. The company benefits from pricing power in the healthcare sector, supported by its established market presence and regulatory approvals.
Regulatory approvals for new drugs
Changes in healthcare policy in Indonesia
Market share growth in Southeast Asia
Fluctuations in raw material costs
Regulatory changes impacting drug pricing and approvals
Technological disruption in drug manufacturing processes
Increasing competition from generic drug manufacturers
Potential market entry by multinational pharmaceutical companies
Low liquidity risk due to high current ratio (3.56)
Potential currency risk from international operations
moderate - As a healthcare provider, Kalbe Farma is somewhat insulated from economic downturns, but overall consumer spending and healthcare budgets can impact growth.
Low - The company's low debt levels (Debt/Equity of 0.01) minimize sensitivity to interest rate changes, though higher rates could impact consumer spending on healthcare products.
minimal - Kalbe Farma's strong balance sheet and low debt levels reduce reliance on credit markets.
value - Given its low valuation metrics and strong fundamentals, Kalbe Farma is attractive to value investors seeking stable growth.
moderate - The stock has experienced significant price fluctuations, evidenced by a 1-year return of -56.7%, indicating moderate volatility.